AI-generated analysis. Always verify with the original filing.
CollPlant Biotechnologies Ltd. is a regenerative medicine company developing rhCollagen-based products for medical aesthetics and 3D bioprinting. This F-1 registers 3,296,000 ordinary shares for resale by selling shareholders upon exercise of February 2026 private placement warrants.
CollPlant Biotechnologies Ltd., an Israel-based regenerative medicine firm, leverages proprietary plant-based rhCollagen technology for products in medical aesthetics like photocurable dermal fillers and 3D-bioprinted breast implants, alongside bioinks for tissue engineering. This F-1 filing registers resale of 3,296,000 ordinary shares by selling shareholders upon exercise of warrants from the February 2026 private placement, where the company sold 1,600,000 RD Shares at $1.25 alongside series A and B warrants, plus 96,000 placement agent warrants at $1.5625. Investors receive no direct proceeds from resales, but potential $4.15 million from full cash exercises could fund working capital and R&D amid a history of significant losses and going concern warnings in 2025 financials showing $124.8 million accumulated deficit and $6.1 million equity on 12.8 million shares outstanding. Capitalization tables reflect pro forma as adjusted equity rising to $11.6 million and shares to 17.7 million post-referenced offerings, with dilution from 1.67 million options, 0.43 million RSUs, and additional warrants. Key risks center on capital needs, clinical uncertainties for aesthetics and bioprinting products, regulatory hurdles, manufacturing reliance on third parties, and Israel-specific geopolitical factors, compounded by competition and IP protection challenges. Forward-looking statements highlight dependencies on partners like AbbVie for dermal fillers, where milestones yielded $12 million but trial next steps remain undecided. Selling shareholders like Bigger Capital (1.2% post-offering), Alumni Capital (1.7%), and Intracoastal (2.3%) hold beneficial ownership subject to 4.99% exercise caps, enabling potential market sales via brokers or negotiated deals. Management includes CEO Yehiel Tal and CFO Eran Rotem, operating under Israeli Companies Law governance with simple majority voting, no cumulative director elections, and board-determined dividends limited by solvency tests. The Nasdaq-listed CLGN shares face overhang from resale potential, exacerbating volatility given low equity base and biotech burn profile. While rhCollagen offers ethical, scalable advantages over animal collagen, commercialization success hinges on trial outcomes and partnerships, positioning this as a high-risk development-stage play for investors eyeing regenerative aesthetics growth.
Offering Amount
$2.0M
Shares Offered
30,000,000
Price Range
$1.25 – $1.25
Issuer Type
Shares Offered
3,296,000
Share Type
ordinary shares, NIS 1.50 par value
Exchange
Nasdaq Capital Market
Ticker
CLGN
Use of Proceeds: No proceeds from resale of ordinary shares by selling shareholders; potential proceeds from cash exercise of Private Placement Warrants for general corporate purposes including working capital and R&D.
Regenerative and aesthetic medicine company focused on medical aesthetics and 3D bioprinting of tissues and organs using recombinant human collagen (rhCollagen) produced in genetically engineered tobacco plants.